Internet-Based Interventions for MDD

NCT ID: NCT04684277

Last Updated: 2021-09-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

440 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-01

Study Completion Date

2023-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The acute and remission depression patients of 18-65 years old were recruited. At the time of enrollment, the demographic, symptomatic, neuropsychological and medication adherence data was collected. After the completion of the baseline assessment and examination, the patients were given antidepressant treatment or antidepressant treatment combined with Internet-based interventions. Clinical evaluation was performed at 1, 3 months (acute patients) and 6, 12 months (remission patients) after treatment, including the medication adherence, therapeutic efficacy, recurrence rate and functional rehabilitation. Through above work, this research is expected to provide clinicians with a set of Internet generalized technologies to improve the compliance and clinical outcomes of patients with depression, and to provide patients with treatment and management of the entire disease cycle.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression Medication Adherence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

antidepressant treatment

recieve antidepressant treatment

Group Type EXPERIMENTAL

antidepressant treatment

Intervention Type DRUG

depression recieve antidepressant treatment

antidepressant treatment combined with Internet-based interventions

recieve antidepressant treatment combined with Internet-based interventions

Group Type EXPERIMENTAL

antidepressant treatment combined with Internet-based interventions

Intervention Type OTHER

depression recieve antidepressant treatment combined with Internet-based interventions

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

antidepressant treatment

depression recieve antidepressant treatment

Intervention Type DRUG

antidepressant treatment combined with Internet-based interventions

depression recieve antidepressant treatment combined with Internet-based interventions

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age 18-65 years old, acute (HAMD17 \> 17) and remission (HAMD17 \< 8) depression

Exclusion Criteria

* other mental illnesses, serious somatic illnesses
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Peking University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Si Tianmei

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tianmei Si, PhD

Role: PRINCIPAL_INVESTIGATOR

Institute of mental health, Peking University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Yunai Su

Beijing, , China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yunai Su, MD

Role: CONTACT

8610-62352880

Jitao Li, MD

Role: CONTACT

8610-82801960

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yunai Su

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SF2020-2-4113

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.